Step 6:
ePRO + eCOA
Smarter Digital Endpoints for Stronger Evidence
Empower patients, caregivers, and clinicians to capture outcomes seamlessly — achieving 91% average ePRO compliance and delivering regulatory-ready data in real time.
Step 6:
Empower patients, caregivers, and clinicians to capture outcomes seamlessly — achieving 91% average ePRO compliance and delivering regulatory-ready data in real time.
Traditional COA collection is fragmented, manual, and error-prone. ObvioGo’s ePRO + eCOA solution unifies the entire process in one easy-to-use platform, enabling faster insights, improved compliance, and scientifically validated evidence for global trials.
ObvioGo's Template Library streamlines study setup by allowing teams to create and reuse standardized activity templates across multiple trials. By centralizing reusable ePRO, eClinRO, eObsRO, and ePerfO configurations, it ensures consistency, control, and faster deployment—reducing setup time while maintaining scientific rigor. Built-in permissions and search tools make it easy for global teams to collaborate securely and efficiently, improving study startup timelines and minimizing configuration errors.
ObvioHealth acts as a single point of coordination, facilitating agreements, terms, and payments with academic, nonprofit, and commercial copyright holders. In collaboration with these partners, we ensure the authorized use of all required COAs (PROs, ClinROs, etc.), supporting compliance and minimizing regulatory exposure.
Each licensed instrument is seamlessly configured within the ObvioGo platform, with formal digitization approval from the copyright holder. We preserve scientific fidelity through rigorous screenshot reviews and certification to ensure every digital instrument maintains the accuracy and integrity of its validated source.
ObvioHealth supports the full linguistic lifecycle by coordinating with trusted partners to manage forward and back translation, cognitive debriefing, and final validation for each market. Through this collaborative process, we ensure culturally adapted, fully validated translations that meet local regulatory standards—enabling compliant, scalable deployment across regions.
ObvioHealth recently completed the first-ever fully virtual urogynecology study to evaluate a medical digital intravaginal device for female stress urinary incontinence. In this randomized trial, pelvic floor muscle contractions were monitored while subjects were completing at-home Kegel exercises. The wand-like device collected data and wirelessly transferred it to a smartphone app downloaded at the start of the study. While there had been initial concerns that older participants might be intimidated by the technology, the results of the study showed that women aged 65 and older had higher rates of completion versus their younger counterparts.
